VAT No Sample Clauses

VAT No. CZ 00098892. established by the decision of the Ministry of Health of the Czech Republic dated 25th November 1990 . (dále jen „Centrum“) (hereinafter referred to as "Center") uzavřená níže uvedeného dne, měsíce a roku podle ustanovení § 1746 odst. 2 zákona č. 89/2012 Sb., občanský zákoník, ve znění pozdějších předpisů (dále jen „Smlouva“): entered into on the below stated day, month and year pursuant to § 1746 sect. 2 of the Act No. 89/2012 Coll., Civil Code, as amended (hereinafter referred to as “Agreement”): Preambule Preamble Vzhledem k tomu, že Bayer požádal Centrum o možnost provést v Centru a o poskytnutí služeb v souvislosti s provedením klinického hodnocení s hodnoceným léčivým přípravkem BAY 1128688 (dále jen „Hodnocený lék“) s názvem Whereas, Bayer has requested Center to assist in and allow conducting in Center of a clinical trial involving the study drug BAY 0000000(hereinafter called the “Study Drug”) entitled Randomizované, placebem kontrolované, dvojitě zaslepené, multicentrické klinické hodnocení s paralelním uspořádáním ke stanovení odpovědi na dávku z hlediska účinnosti a bezpečnosti ústního podání BAY 1128688 u pacientek se symptomatickou endometriózou po 12 týdnech léčby s číslem Bayer 17472 (dále jen „Studie“), které je blíže popsáno v protokolu verze 1.0 z 6.7.2017 /, včetně jeho následných změn (jeho poslední schválená verze se dále označuje jen jako „Protokol“), pod vedením zkoušejícího, jímž byl společností Bayer určen X (dále jen „Zkoušející), A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose- response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with symptomatic endometriosis over a 12-week treatment period with the Bayer number 17472 (hereinafter referred to as "Study") as described in more detail in the protocol version 1.0 dated 6th July 2017 as amended from time to time (latest approved version hereinafter referred to as "Protocol") by and under the supervision of the investigator appointed by the company Bayer and who shall be X (hereinafter referred to as the “Investigator”), vzhledem k tomu, že zadavatelem Studie je společnost Bayer AG, se sídlem v Leverkusen, 51368, Německo, zapsaná u Místního soudu v Kolíně nad Rýnem, pod číslem HRB 48248 rejstříku společností, , jež je společností propojenou se společností Bayer, a která pověřila společnost Bayer výkonem svých práv a povinností v rámci provádění Studie v České republice, společnost ...
Sample 1
AutoNDA by SimpleDocs
VAT No. Both parties declare that they agree to switch to the electronic dispatch of the invoices issued by Xxxxxxxxxxx Interowa in strict accordance with following points:
Sample 1
VAT No. ES B15964521, represented by Xxxxxx Xxxxx, president, hereinafter the Supplier, of the other part, jointly and separately referred to as the Parties, in accordance with the results of the Tender for the “Mnova Suite 3-Year Updates & Support (2017., 2018. and 2019).”, Id. No. OSI 2016/30 MI, hereinafter the Tender, organized by the Latvian Institute of Organic Synthesis, and the Bid submitted by the Supplier, hereby enter into the Contract:
Sample 1
VAT No represented by: ……………………………………………………… ……………………………………………………… (hereinafter also referred to as "Contractual Partner") Nemak and the Contractual Partner hereinafter also individually referred to as "Party" or jointly as the "Parties". Nemak and the Contractual Partner intend to work together on the project entitled “BMW_DAIMLER Washing machine with automatic loading” In order to do so Nemak and the Contractual Partner will have to exchange technical and/or business information which the respective other Party has created and which constitutes secret know-how. Therefore the following is agreed between Nemak and the Contractual Partner. UMOWA O ZACHOWANIU POUFNOŚCI pomiędzy Nemak Poland sp. z o.o. z siedzibą w Bielsku – Białej (zwanej dalej „Nemak”) A …………………………………………………… ……………………………………………………… ......................................
Sample 1
VAT No. CZ 00098892. established by the decision of the Ministry of Health of the Czech Republic dated 25th November 1990 . (dále jen „Centrum“) (hereinafter referred to as "Center") uzavřená níže uvedeného dne, měsíce a roku podle ustanovení § 1746 odst. 2 zákona č. 89/2012 Sb., občanský zákoník, ve znění pozdějších předpisů (dále jen „Smlouva“): entered into on the below stated day, month and year pursuant to § 1746 sect. 2 of the Act No. 89/2012 Coll., Civil Code, as amended (hereinafter referred to as “Agreement”):
Sample 1
VAT No. Registered office/Physical address: ...........................................................................................................................................................................................
Sample 1
VAT No. (herein represented by ...................................) (hereinafter called "the Tenant") of the Second Part The Landlord hereby lets to the Tenant who hereby hires the premises described in Section 3 of the Schedule annexed hereto on the terms and conditions as set out in the said Schedule and General Conditions annexed hereto. REF: CST009-HO6320 ------------------------------ "FOR OFFICE USE ONLY" TERMS AS AGREED ------------------- NEGOTIATOR VERIFIED TO MASTER FILE ------------------- PROP. ADMIN. ------------------------------ INITIAL HERE [ILLEGIBLE] Fedsure Properties (Pty) Ltd. Revised Version - 25 June 1999 -------------------------------------------------------------------------------- SCHEDULE --------------------------------------------------------------------------------
Sample 1
AutoNDA by SimpleDocs
VAT No. Bank: ............................................................... Branch Code: ......................................
Sample 1

Related to VAT No

  • Nonpetition Covenant; No Recourse Each of (i) the Warrant Holder by its acceptance thereof, and (ii) the Warrant Agent agrees, that it shall not (and, in the case of the Warrant Holder, that it shall not direct the Warrant Agent to), until the date which is one year and one day after the payment in full of the Certificates and all other securities issued by the Trust, the Depositor or entities formed, established or settled by the Depositor, acquiesce, petition or otherwise invoke or cause the Trust, the Depositor, or any such other entity to invoke the process of the United States of America, any State or other political subdivision thereof or any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government for the purpose of commencing or sustaining a case by or against the Trust, the Depositor or any such other entity under a federal or state bankruptcy, insolvency or similar law or appointing a receiver, liquidator, assignee, trustee, custodian, sequestrator or other similar official of the Trust, the Depositor or any such other entity or all or any part of the property or assets of Trust, the Depositor or any such other entity or ordering the winding up or liquidation of the affairs of the Trust, the Depositor or any such other entity.

  • Customer is Liable to Bank Even if it is Acting for Another Person If Customer is acting as an agent for a disclosed or undisclosed principal in respect of any transaction, cash, or Financial Asset, Bank nevertheless shall treat Customer as its principal for all purposes under this Agreement. In this regard, Customer shall be liable to Bank as a principal in respect of any transactions relating to the Account. The foregoing shall not affect any rights Bank might have against Customer's principal.

  • No Default; No Waiver Except for payment delinquencies continuing for a period of not more than 30 days as of the Cut-Off Date, the records of the Servicer did not disclose that any default, breach, violation or event permitting acceleration under the terms of the Receivable existed as of the Cut-Off Date or that any continuing condition that with notice or lapse of time, or both, would constitute a default, breach, violation or event permitting acceleration under the terms of the Receivable had arisen as of the Cut-Off Date and the Seller has not waived any of the foregoing.

  • Adequate Information; No Reliance The Undersigned acknowledges and agrees on behalf of itself and each Holder that (a) the Undersigned has been furnished with all materials it considers relevant to making an investment decision to enter into the Transactions and has had the opportunity to review (and has carefully reviewed) the Company’s filings and submissions with the SEC, including, without limitation, all information filed or furnished pursuant to the Exchange Act, (b) the Undersigned has had a full opportunity to ask questions of and receive answers from the Company or any person or persons acting on behalf of the Company concerning the Company, its business, operations, financial performance, financial condition and prospects and the terms and conditions of the Transactions, (c) the Undersigned and each Holder has had the opportunity to consult with their respective accounting, tax, financial and legal advisors to be able to evaluate the risks involved in the Transactions and to make an informed investment decision with respect to such Transactions, (d) each Holder has evaluated the tax and other consequences of the Transactions and ownership of the Exchange Shares with its tax, accounting, financial and legal advisors to be able to evaluate the risks involved in the transactions contemplated by this Agreement and to make an informed investment decision with respect to the Transactions, including, without limitation, whether the exchange contemplated hereby will result in any adverse tax consequences to the such Holder, (e) neither the Company nor the Financial Advisor is acting as a fiduciary or financial or investment advisor to the Undersigned or any Holder, (f) neither the Undersigned nor any Holder is relying, and none of them has relied, upon any statement, advice (whether accounting, tax, financial, legal or other), representation or warranty made by the Company or any of its Affiliates or representatives including, without limitation, the Financial Advisor, except for the representations and warranties expressly made by the Company in Article III, (g) neither the Financial Advisor nor any of its affiliates or any of its control persons, officers, directors or employees shall be liable to the Holders in connection with the Transactions and (h) each Holder had a sufficient amount of time to consider whether to participate in the Transactions and that neither the Company nor the Financial Advisor has placed any pressure on such Holder to respond to the opportunity to participate in the Transactions. Each of the Undersigned and each Holder is able to fend for itself in the Transactions; has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its prospective investment in the Exchange Shares; has the ability to bear the economic risks of its prospective investment and can afford the complete loss of such investment; acknowledges that investment in the Exchange Shares involves a high degree of risk; has, independently and without reliance upon the Company or the Financial Advisor, made its own analysis and decision to participate in the exchange contemplated hereby on the terms and conditions set forth in this Agreement; and was given a meaningful opportunity to negotiate the terms of the Transactions.

  • No Obligation to Mitigate Damages; No Effect on Other Contractual Rights (a) The Executive shall not be required to mitigate damages or the amount of any payment provided for under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by the Executive as the result of employment by another employer after the Date of Termination, or otherwise.

  • Confirmation of no default The Borrower will, within 2 Business Days after service by the Agent of a written request, serve on the Agent a notice which is signed by 2 directors of the Borrower and which:

  • Entire Agreement; No Third Party Beneficiaries; Rights of Ownership This Agreement (including the documents and the instruments referred to herein) constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof, and is not intended to confer upon any person other than the parties hereto any rights or remedies hereunder.

  • No Changes that Materially Affect Obligations Notwithstanding anything in this Agreement to the contrary, the Fund agrees not to make any modifications to its registration statement or adopt any policies which would affect materially the obligations or responsibilities of PFPC Trust hereunder without the prior written approval of PFPC Trust, which approval shall not be unreasonably withheld or delayed.

  • Corporate Authority Relative to this Agreement; No Violation (a) Parent and Merger Sub have all requisite corporate power and authority to enter into this Agreement to perform its obligations hereunder and to consummate the Transactions, including the Merger. The execution, delivery and performance by Parent and Merger Sub of this Agreement and the consummation of the Transactions have been duly and validly authorized by the Parent Board of Directors and, except for the filing of the Articles of Merger with the Registrar or Deputy Registrar of Corporations of the Republic of the Xxxxxxxx Islands, no other corporate proceedings on the part of Parent or any Parent Subsidiary are necessary to authorize the consummation of the Transactions. Prior to the execution of this Agreement, the Parent Board of Directors has unanimously adopted resolutions approving this Agreement and the Transactions, including the Merger, and authorizing the execution, delivery and performance of this Agreement. Parent, as sole shareholder of Merger Sub, has duly executed and delivered a written consent adopting this Agreement, such written consent by its terms to become effective immediately following the execution of this Agreement and the board of directors of Merger Sub has unanimously approved this Agreement and the Transactions, including the Merger, and authorized the execution, delivery and performance of this Agreement. This Agreement has been duly and validly executed and delivered by Parent and Merger Sub and, assuming this Agreement constitutes the valid and binding agreement of Partnership, constitutes the valid and binding agreement of Parent and Merger Sub, enforceable against Parent and Merger Sub in accordance with its terms, subject to the Enforceability Exceptions.

  • WITNESSES THAT WHEREAS A. The Company and the Trustee have entered into an indenture (the "Indenture") dated as of November 30, 2004 providing for the issuance of 8.00% Senior Subordinated Notes due 2012 of the Company (the "Securities"); and

Time is Money Join Law Insider Premium to draft better contracts faster.